Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma
Pathology - Research and Practice · 2026-05 · 281 · 156407
DOI: 10.1016/j.prp.2026.156407 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2026-05. Verfasst von Yuqing Wei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Postgraduate Training Base of Jinzhou Medical University (The 960th Hospital of the PLA Joint Logistic Support Force), J…. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Proto-Oncogene Proteins c-ret, Thyroid Cancer, Papillary, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: Shandong Province Natural Science Foundation.
Abstract (Originalsprache)
Thyroid cancer represents the fastest-growing endocrine malignancy worldwide, with papillary thyroid carcinoma (PTC) being its predominant pathological subtype. RET fusion is a key driver genetic alteration in PTC, closely associated with enhanced tumor invasiveness and poorer prognosis in some cohorts. This review systematically summarizes the molecular pathogenesis of RET fusion-positive PTC, encompassing the structure and function of the RET proto-oncogene and its encoded protein, the molecular characteristics of fusion events (predominantly CCDC6-RET and NCOA4-RET), the mechanisms underlying sustained activation of classical signaling pathways, and the novel regulatory mechanism of liquid-liquid phase separation. Furthermore, the review elaborates on the clinical efficacy of highly selective RET inhibitors (selpercatinib and pralsetinib), including their breakthroughs in pediatric patients and radioactive iodine-refractory cases. Primary and acquired resistance mechanisms (on-target mutations, bypass activation) and corresponding strategies (next-generation inhibitors, combination therapies) are also analyzed. By integrating recent advances in basic and clinical research, this review provides a comprehensive reference for the precision diagnosis and treatment, mechanistic investigation, and drug development for RET fusion-positive PTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The Postgraduate Training Base of Jinzhou Medical University (The 960th Hospital of the PLA Joint Logistic Support Force), Jinan 250031, China; Department of Pathology, The 960th Hospital of the…
- Department of General Surgery, The 960th Hospital of the PLA Joint Logistic Support Force, Jinan 250031, China.
- Department of Endocrinology, The 960th Hospital of the PLA Joint Logistic Support Force, Jinan 250031, China.
- Department of Pediatrics, The Second Qilu Hospital of Shandong University, Jinan 250033, China. Electronic address: 78155932@qq.com.
Förderung
- Shandong Province Natural Science Foundation
Zitieren
APA
Wei, Y., Zhang, Y., Zhang, Z., Wang, Y., & Li, P. (2026). Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma. Pathology - Research and Practice, 281, 156407. https://doi.org/10.1016/j.prp.2026.156407
Vancouver
Wei Y, Zhang Y, Zhang Z, Wang Y, Li P. Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma. Pathology - Research and Practice. 2026;281:156407. doi:10.1016/j.prp.2026.156407
BibTeX
@article{Wei2026,
author = {Wei, Yuqing and Zhang, Yan and Zhang, Zongjing and Wang, Yayun and Li, Peifeng},
title = {Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma},
journal = {Pathology - Research and Practice},
year = {2026},
volume = {281},
pages = {156407},
doi = {10.1016/j.prp.2026.156407}
}
EUVIMED